Viridian Therapeutics sees stock soar after Phase III TED success
Dec 17, 2024 · Viridian Therapeutics’s stock has jumped after a Phase III trial of veligrotug met all endpoints and was well tolerated in patients with chronic thyroid eye disease (TED).. The …
Most significant clinical trials of 2024
Dec 23, 2024 · There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines …
GSK ceases HSV vaccine - a chance for Moderna and BioNTech
Sep 25, 2024 · GSK recently announced the discontinuation of its herpes simplex virus (HSV) therapeutic vaccine candidate, GSK3943104, following the failure of a Phase I/II clinical trial to …
MHRA expects new UK clinical trial regulation implementation by …
Oct 16, 2024 · Between 2022 and 2023, the MHRA undertook a consultation period surrounding a new legislative framework for clinical trials in the UK. The MHRA said the new regulation will …
MSD reports outcomes from Phase III trial of pembrolizumab
Nov 20, 2024 · MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous Keytruda (pembrolizumab) administration, …
A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
Oct 1, 2024 · Cobenfy is also being developed as an adjunctive therapy in patients who have an inadequate response to atypical antipsychotic monotherapy. The ongoing Phase III ARISE trial …
Imugene doses first Australian subject in DLBCL treatment trial
Jan 3, 2025 · Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene …
GSK reports positive findings from Phase III RSV vaccine trial
Oct 9, 2024 · Following the initial season, 12,469 individuals from the vaccine group were re-randomised to receive either the RSV vaccine or a placebo. The study then measured the …
J&J reports positive outcomes from NSCLC combo therapy trial
Jan 8, 2025 · The combination therapy is intended to treat NSCLC in individuals with certain mutations. Credit: Ei Ywet / Shutterstock. Johnson & Johnson (J&J) has reported positive …
AHA 2024: Zerlasiran shows promising Phase II results for elevated ...
Nov 19, 2024 · Dr. Steven Nissen, MD chairman and chief academic officer of the Heart and Vascular Institute at the Cleveland Clinic and professor of medicine at the Lerner College of …